{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:18:13Z","timestamp":1793787493211,"version":"4.6.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Amid the current US opioid crisis, hepatitis C virus (HCV) infection rates continue to rise in young adults, including among pregnant women, yet few studies describe linkage to care and treatment in pregnant or postpartum women with HCV infection. We used electronic health record data to estimate HCV treatment rates for postpartum women before (January 2014\u2010September 2016) and during (October 2016\u2010March 2018) implementation of a maternal\u2013infant HCV linkage program in combination with a multidisciplinary clinic to colocate mother and infant care. Using Poisson regression models, we compared HCV treatment initiation rates, adjusting for demographics, substance use, and treatment. From January 2014 through March 2018, 343 women who were HCV seropositive delivered at our institution. Of these, 95% completed HCV nucleic acid testing and 255 women had chronic HCV infection. Mean age was 30\u00a0years, 96% were publicly insured, and 94% had documented substance use. HCV treatment initiation increased from 28\/164 (17.1%) women with chronic HCV infection in the preintervention period to 16\/66 (24.2%) with the linkage\u2010only intervention and 13\/25 (52.0%) with the linkage intervention and colocated care. Adjusted analyses demonstrated that women delivering during the intervention period initiated HCV treatment at 2.40 times (95% confidence interval [CI], 1.10\u20105.25; linkage only) and 3.36 times (95% CI, 1.57\u20107.17; linkage and colocated care) the rate of women delivering preintervention. Women on buprenorphine had higher HCV treatment initiation rates compared with those on methadone (rate ratio, 2.10; 95% CI, 1.05\u20104.21). <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> HCV linkage to care and treatment rates improved in the setting of mother\u2013infant linkage and colocated care interventions. Perinatal care may represent a critical venue to identify, link, and treat women for HCV infection to improve their own health and prevent transmission to subsequent pregnancies.<\/jats:p>","DOI":"10.1002\/hep4.1748","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:46:13Z","timestamp":1625168773000},"page":"1543-1554","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care"],"prefix":"10.1097","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-8865","authenticated-orcid":false,"given":"Rachel L.","family":"Epstein","sequence":"first","affiliation":[{"name":"Department of Medicine,Section of Infectious Diseases,Boston University School of Medicine,Boston,MA,USA"},{"name":"Department of Pediatrics,Section of Infectious Diseases,Boston University School of Medicine,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Moloney","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,Section of Infectious Diseases,Boston University School of Medicine,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Garfinkel","sequence":"additional","affiliation":[{"name":"Boston University School of Public Health,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Saia","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology,Boston University School of Medicine,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha M.","family":"Wachman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,Boston University School of Medicine,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lodi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics,Boston University School of Public Health,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen I.","family":"Pelton","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,Section of Infectious Diseases,Boston University School of Medicine,Boston,MA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"hep41748-bib-0001-20241015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid\u2010involved overdose deaths\u2014United States, 2017\u20102018","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep41748-bib-0002-20241015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2017.01.003","article-title":"Non\u2010medical opioid use and sources of opioids among pregnant and non\u2010pregnant reproductive\u2010aged women","volume":"174","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"hep41748-bib-0003-20241015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization\u2014United States, 1999\u20102014","volume":"67","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"key":"hep41748-bib-0004-20241015","doi-asserted-by":"crossref","first-page":"833","DOI":"10.15585\/mmwr.mm6839a1","article-title":"National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization\u2014United States, 2000\u20132015","volume":"68","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep41748-bib-0005-20241015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/M16-2350","article-title":"Hepatitis C virus infection among reproductive\u2010aged women and children in the United States, 2006 to 2014","volume":"166","year":"2017","journal-title":"Ann Intern Med"},{"key":"hep41748-bib-0006-20241015","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20101965","volume":"61","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"hep41748-bib-0007-20241015","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health\u2010care settings","volume":"55","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl. 1","key":"hep41748-bib-0008-20241015","first-page":"A87.","article-title":"Hepatitis C virus risk\u2010based vs. universal screening among pregnant women: implementation and cost\u2010effectiveness analysis [Abstract]","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep41748-bib-0009-20241015","first-page":"371","article-title":"Hepatitis C virus universal screening versus risk based selective screening during pregnancy","volume":"8","year":"2015","journal-title":"J Neonatal\u2010Perinat Med"},{"key":"hep41748-bib-0010-20241015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11524-015-9945-4","article-title":"Comparison of risk\u2010based hepatitis C screening and the true seroprevalence in an urban prison system","volume":"92","year":"2015","journal-title":"J Urban Health"},{"key":"hep41748-bib-0011-20241015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD\u2010IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"hep41748-bib-0012-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults\u2014United States, 2020","volume":"69","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"hep41748-bib-0013-20241015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/apt.15291","article-title":"The impact of direct\u2010acting anti\u2010virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States","volume":"50","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41748-bib-0014-20241015","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/cid\/ciy586","article-title":"Universal screening of pregnant women for hepatitis C: the time is now","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"hep41748-bib-0015-20241015","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study","volume":"1","year":"2020","journal-title":"Lancet Microbe"},{"issue":"Suppl. 1","key":"hep41748-bib-0016-20241015","article-title":"Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa","volume":"19","year":"2019","journal-title":"BMC Infect Dis"},{"key":"hep41748-bib-0017-20241015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpeds.2018.07.006","article-title":"Perinatal transmission of hepatitis C virus: defining the cascade of care","volume":"203","year":"2018","journal-title":"J Pediatr"},{"key":"hep41748-bib-0018-20241015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/08897077.2015.1118720","article-title":"Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: a retrospective cohort study","volume":"37","year":"2016","journal-title":"Subst Abuse"},{"key":"hep41748-bib-0019-20241015","first-page":"1778","article-title":"Hepatitis C cascade of care among pregnant women on opioid agonist pharmacotherapy attending a comprehensive prenatal program","year":"2017","journal-title":"Matern Child Health J"},{"key":"hep41748-bib-0020-20241015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/hep4.1401","article-title":"Hepatitis C screening in an underserved U.S. cohort of reproductive age women","volume":"3","year":"2019","journal-title":"Hepatol Commun"},{"key":"hep41748-bib-0021-20241015","article-title":"Risk\u2010based hepatitis C screening in pregnancy is less reliable than universal screening: a retrospective chart review","volume":"5","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"hep41748-bib-0023-20241015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"hep41748-bib-0024-20241015","article-title":"Children and families of the opioid epidemic: under the radar","volume":"49","year":"2019","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"hep41748-bib-0025-20241015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","year":"2006","journal-title":"J Viral Hepat"},{"key":"hep41748-bib-0027-20241015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11606-020-05701-9","article-title":"HCV testing and treatment in a national sample of US federally qualified health centers during the opioid epidemic","volume":"35","year":"2020","journal-title":"J Gen Intern Med"},{"key":"hep41748-bib-0028-20241015","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"hep41748-bib-0029-20241015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","article-title":"The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC\u2010HTC)","volume":"12","year":"2016","journal-title":"EBioMedicine"},{"key":"hep41748-bib-0030-20241015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/bfm.2017.0172","article-title":"Examination of hospital, maternal, and infant characteristics associated with breastfeeding initiation and continuation among opioid\u2010exposed mother\u2010infant dyads","volume":"13","year":"2018","journal-title":"Breastfeed Med"},{"key":"hep41748-bib-0031-20241015","article-title":"Integration of hepatitis C treatment in a primary care federally qualified health center; Philadelphia, Pennsylvania, 2015\u20102017","volume":"12","year":"2019","journal-title":"Infect Dis (Auckl)"},{"key":"hep41748-bib-0032-20241015","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1307","article-title":"Effectiveness of ledipasvir\/sofosbuvir and sofosbuvir\/velpatasvir in people who inject drugs and\/or those in opioid agonist therapy","volume":"3","year":"2019","journal-title":"Hepatol Commun"},{"key":"hep41748-bib-0033-20241015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drugpo.2019.05.010","article-title":"Cost\u2010effectiveness of integrating buprenorphine\u2010naloxone treatment for opioid use disorder into clinical care for persons with HIV\/hepatitis C co\u2010infection who inject opioids","volume":"72","year":"2019","journal-title":"Int J Drug Policy"},{"key":"hep41748-bib-0034-20241015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11904-018-0396-x","article-title":"Integrated models of care for individuals with opioid use disorder: how do we prevent HIV and HCV?","volume":"15","year":"2018","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1748","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T22:22:51Z","timestamp":1729030971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1748","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"2021-01-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}